STAT+: Takeda strikes a rebate deal for lung cancer drug as health plans look to value-based agreements
In another bid to address the cost of prescription medicines, Takeda Pharmaceuticals (TAK) and 32PointHealth have reached a deal in which the drug maker will offer a “significant rebate” for a lung cancer treatment if the medication proves ineffective for patients.
Specifically, the deal involves Alunbrig, which is approved to treat non-small cell lung cancer. If a patient covered by 32PointHealth — the second-largest health plan in New England — does not remain on the drug for three months or more due to effectiveness or tolerability, Takeda will return an unspecified amount of money to the insurer. The drug has a $17,000 list price for a month’s treatment.
Continue to STAT+ to read the full story…
